Amphetamines |
|
|
|
|
|
|
d-amphetamine |
Dexedrine |
Tablets: 5, 10 mg |
3–6 |
|
Dexedrine |
Spansules: 5, 10, 15 mg |
Spansule |
ProCentra |
Oral solution: 5 mg/5 mL |
Mixed amphetamine/dextroamphetamine |
Adderall |
Tablets: 5, 7.5, 10, 12.5, 15, 20, 30 mg |
4–6 |
|
Adderall XR |
Capsules: 5, 10, 15, 20, 25, 30 mg |
8–10 |
Capsule with 1:1 ratio of immediate-release to delayed-release beads |
Lisdexamfetamine dimesylate |
Vyvanse |
Capsules: 20, 30, 40, 50, 60, 70 mg |
|
Inactive prodrug in which l-lysine is chemically bonded to d-amphetamine |
d-methamphetamine |
Desoxyn |
Tablet: 5 mg |
|
|
Methylphenidates |
|
|
|
|
|
|
Methylphenidate |
Ritalin |
Tablets: 5, 10, 20 mg |
3–4 |
|
Methylin |
Tablets, chewable: 2.5, 5, 10 mg |
3–4 |
|
Oral solution: 5 mg/5 mL, 10 mg/5 mL (500 mL) |
3–4 |
|
Ritalin sustained release |
Tablet: 20 mg |
5–8 |
|
Ritalin LA |
Capsules: 10, 20, 30, 40 mg |
8–9 |
Capsule with 1:1 ratio of immediate-release beads to delayed-release beads |
Metadate ER |
Tablets: 10, 20 mg |
5–8 |
|
Metadate CD |
Capsules: 10, 20, 30 mg |
8–9 |
Capsule with 3:7 ratio of immediate-release beads to delayed-release beads |
Concerta |
Tablets: 18, 27, 36, 54 mg |
10–12 |
Ascending profile, osmotic release oral system technology |
Daytrana |
Transdermal patch: 10, 15, 20, 30 mg/9 h |
9 |
Delivery rate of 1.1, 1.6, 2.2, 3.3 mg/h for the patches, respectively, based on 9-h wear times in patients aged 6–12 y |
|
Quillivant XR |
Oral suspension: 25mg/5mL |
10–12 |
|
Dexmethylphenidate |
Focalin |
Tablets: 2.5, 5, 10 mg |
|
d isomer of methylphenidate, twice as potent as racemic methylphenidate |
Focalin XR |
Capsules: 5, 10, 20 mg |